Current treatment of lupus nephritis: an overview of the new guidelines.

Abstract

Introduction: Given the relevance of renal involvement in systemic lupus erythematosus (SLE) and new approaches to the disease and its treatment, this article aimed to synthesize the main updates in the diagnosis, management, and treatment of lupus nephritis (LN), based on recent publications of international reference guidelines in nephrology and rheumatology, in addition to highlighting aspects of interest from the 2024 national guidelines of the Brazilian Society of Rheumatology (SBR). The treatments for each class of lupus nephritis are described, as well as the therapeutic targets, underlining similarities and differences between the guidelines. In general, they recommend that induction ("initial") treatment of proliferative classes be performed with monotherapy using mycophenolate or intravenous cyclophosphamide, or with multitarget regimens, using corticosteroids, mycophenolate or cyclophosphamide, and a calcineurin inhibitor or belimumab as a third drug. A change in therapy should be considered if the expected response target is not achieved, which presents subtle differences among current consensus guidelines. Maintenance ("subsequent") treatment should preferably be performed with mycophenolate, azathioprine, or multi-target therapies. Emerging scientific evidence has provided treatment options that impact the management of lupus nephritis, thereby justifying the publication of new guidelines in recent months. Critically analyzing these guidelines may assist in decision-making for the individualized treatment of individuals with this disease.